摘要
目的:研究12-脂氧合酶(12-lipoxygenase,12-LOX)在神经胶质瘤中的表达及其临床意义。方法:免疫组织化学法检测40例神经胶质瘤组织和10例正常脑组织中12-LOX表达,结合临床随访资料探讨其表达与预后的相关性。结果:正常脑组织中12-LOX呈弱阳性表达,神经胶质瘤组织中强阳性表达率为72.5%,差异有统计学意义(P<0.05)。12-LOX强阳性表达与神经胶质瘤病理级别相关,差异有统计学意义(P=0.012),与患者性别、年龄、肿瘤大小、KPS评分无关。12-LOX强阳性表达患者中位无瘤生存期明显低于与弱阳性表达患者(P<0.05)。结论:12-LOX在神经胶质瘤中异常表达,其表达差异与神经胶质瘤的病理级别相关,与预后密切相关。
Objective： To investigate the expression and clinical significance of 12-1ipoxygenase （12-LOX） in glioma. Methods： 12-LOX expression in 40 glioma cases and 10 normal human-brain tissues was assayed by immunohistochemistry. Clinicopathological data were analyzed to reveal the association between 12-LOX expression and prognosis of glioma patients. Results： 12-LOX was weak- ly expressed in the normal human brain tissues, whereas 12-LOX was strongly expressed （72.5%） in glioma tissues （P〈0.05）. The strong 12-LOX expression was correlated with the histopathological grading of glioma （P=0.012）, whereas 12-LOX expression was not correlated with factors such as patient gender and age, tumor size, and Karnofsky Performance Score. Median survival time was longer in the group with low 12-LOX expression （25.6 months） than in the group with high 12-LOX expression （13.2 months） （P〈0.05）. Con- clusion： Abnormal 12-LOX expression is implicated in glioma. 12-LOX expression was correlated with the histopathological grading of ~lioma and was closely associated with patient prognosis.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2015年第19期953-956,共4页
Chinese Journal of Clinical Oncology
基金
皖南医学院第一附属医院引进人才项目(编号:2014047)资助~~
